Joint Study by Rosetta Genomics Ltd. and NYU Langone Medical Center Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients

REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published online on February 16th, 2010, and are set to be published in the March 1st issue of the American Association for Cancer Research’s journal, Cancer Research. The study, “Hsa-Mir-29c* is Linked to the Prognosis of Malignant Pleural Mesothelioma,” demonstrates the potential of a single microRNA to act as an independent prognostic factor for time to progression as well as survival after surgery. The abstract of the study may be viewed online at:

Back to news